Agency Information Collection Activities; Proposed Collection; Comment Request; Antimicrobial Animal Drug Distribution Reports Under Section 105 of the Animal Drug User Fee Amendments of 2008, 55046-55048 [E9-25671]
Download as PDF
55046
Federal Register / Vol. 74, No. 205 / Monday, October 26, 2009 / Notices
factors for physical, non-physical, and
electronic WPV in teachers and
paraprofessionals in Pennsylvania; (3)
Measure the impact of WPV on job
satisfaction and quality of life. These
goals are solely based on the State of
Pennsylvania and are not based on a
nation wide study.
NIOSH is proposing to conduct a
population-based, cross-sectional survey
among teachers and paraprofessionals in
the State of Pennsylvania. Paper-andpencil surveys will be mailed to
potential participants through the
Pittsburgh Federation of Teachers (PFT),
Philadelphia Federation of Teachers
(PA–AFT), and the Pennsylvania State
Education Association (PSEA). Since
approximately 90% of teachers and 65%
of paraprofessionals in the State of
Pennsylvania hold membership in one
of these three unions and no known
State-wide database exists that includes
both teachers and paraprofessionals, a
sample of eligible participants will be
drawn using State-based union records.
A stratified random sample will be
drawn to ensure representativeness on
important dimensions such as gender of
participant and urban-rural status of the
school district. In conjunction with each
participating union, study packets
consisting of an introduction letter,
paper-and-pencil survey, and nonresponse form will be mailed to eligible
participant’s home addresses. The
questionnaire is a paper-and-pencil
survey and provides information on the
following categories: demographics,
occupation, physical assault
characteristics, non-physical assault
characteristics, electronic aggression
characteristics, job satisfaction, and
quality of life.
The sample size for the crosssectional survey is estimated to be
approximately 5,000 teachers and
paraprofessionals. This estimate is
based on the number of reported
teachers and paraprofessionals
represented by the three unions
participating in this study and on an
80% response rate that is comparable to
the response rate of previously
conducted surveys in similar
populations. Pilot test data
demonstrates that respondents should
take approximately 30 minutes to
complete the paper-and-pencil survey,
resulting in an annualized burden
estimate of 2,500 hours. Participation in
the study is completely voluntary.
This survey will also utilize the skills
and time of a variety of union office and
administrative staff for the preparation
of the survey packets. The exact number
of administrative staff utilized at each
union location, as well as the additional
work demands placed on them has yet
to be determined, though our best guess
is 13 individuals. It is estimated that
three office support staff from the
Pittsburgh Federation of Teachers, six
from the Pennsylvania State Education
Association, and four from the
Philadelphia Federation of Teachers
will be needed for a grand total of 13
support staff personnel. Additional
work activities could include:
Preparation of the sampling frame
database and non-respondent database,
printing of mailing labels, affixation of
mailing labels onto survey packets, and
e-mail and/or phone communication
with NIOSH. For each mailing, we
estimate that each of the 13
administration assistants will dedicate
two hours to the mailing. So, for each
mailing, a grand total of 26 hours will
be burdened. There will be three
separate mailings for a grand total
burden of 78 burden hours.
There are no costs to the respondents
other than their time. The total
estimated annual burden hours are
2,578.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Elementary and Secondary School Employees ..........................................................................
Office & Administrative Support Occupations .............................................................................
Dated: October 19, 2009.
Maryam Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E9–25649 Filed 10–23–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
mstockstill on DSKH9S0YB1PROD with NOTICES
[Docket No. FDA–2009–N–0512]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Antimicrobial
Animal Drug Distribution Reports
Under Section 105 of the Animal Drug
User Fee Amendments of 2008
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Nov<24>2008
15:19 Oct 23, 2009
Jkt 220001
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and including each
proposed extension of a collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
reporting and recordkeeping
requirements for antimicrobial animal
drug distribution as required by Section
105 of the Animal Drug User Fee
Amendments of 2008 (ADUFA).
DATES: Submit written or electronic
comments on the collection of
information by December 28, 2009.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
5,000
13
Number of responses per
respondent
1
3
Average
burden per
response
(in hours)
30/60
2
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3793.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
E:\FR\FM\26OCN1.SGM
26OCN1
55047
Federal Register / Vol. 74, No. 205 / Monday, October 26, 2009 / Notices
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Antimicrobial Animal Drug
Distribution Reports Under Section 105
of the Animal Drug User Fee
Amendments of 2008—Federal Food,
Drug, and Cosmetic Act, Section
512(1)(3) (OMB Control Number 0910–
NEW)
Section 105 of ADUFA amended
section 512 of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
360b) to require that the sponsor of each
new animal drug that contains an
antimicrobial agent submit an annual
report to FDA on the amount of each
antimicrobial active ingredient in the
drug that is sold or distributed for use
in food-producing animals, including
information on any distributor-labeled
product. The legislation was enacted to
address the problem of antimicrobial
resistance and to help ensure that FDA
has the necessary information to
examine safety concerns related to the
use of antibiotics in food-producing
animals (154 Congressional Record
H7534).
Each report must specify: (1) The
amount of each antimicrobial active
ingredient by container size, strength,
and dosage form, (2) quantities
distributed domestically and quantities
exported and (3) a listing of the target
animals, indications, and production
classes that are specified on the
approved label of the product.
The first report must be submitted not
later than March 31, 2010. The report
must cover the period of the preceding
calendar year and include separate
information for each month of the
calendar year. The reports required
under section 105 of ADUFA are
required to be separate from periodic
drug experience reports that are
required under 21 CFR 514.80(b)(4)
(OMB Control No. 0910–0284).
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
FD&C Act
Section 512(1)(3)
No. of
Respondents
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total
Hours
Capital
Cost
Annual Reports for
Sponsors with Active Applications
29
6.7
194
80
15,520
Annual Reports for
Sponsors with Inactive Applications
23
4.0
92
1
92
Total
1 There
15,612
$107,880
$107,880
are no operating and maintenance costs associated with this collection of information.
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
FD&C Act
Section 512(1)(3)
No. of
Respondents
All Applicants
Annual Frequency of
Recordkeeping
34
Total Annual
Records
1
Hours per
Record
34
2
Total
mstockstill on DSKH9S0YB1PROD with NOTICES
1 There
Total Hours
68
68
are no capital costs or operating and maintenance costs associated with this collection of information.
The reporting burden estimates,
including the total number of annual
responses, are based on the number of
sponsors and approved applications for
antimicrobial drug products in foodproducing animals. The annual
frequency of responses was calculated
as the total annual responses divided by
the number of respondents.
The agency arrived at the estimates
for reporting as follows: There are 34
sponsors with approved applications for
antimicrobial drugs for food-producing
animals. There are 29 animal drug
manufacturers with 194 approved
VerDate Nov<24>2008
15:19 Oct 23, 2009
Jkt 220001
applications for antimicrobial drugs for
food-producing animals for which the
drugs are being actively marketed
(active applications). Additionally, there
are 93 approved applications for
antimicrobial drugs for food-producing
animals for which the drugs are not
being marketed (inactive applications),
owned by 23 animal drug
manufacturers.
Regarding the reporting burden
associated with the collection of
information, FDA believes that the large
majority of the burden will be incurred
by industry in the first year in which
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
reporting is required to design a report
that meets the requirements of section
512(l)(3) of the act. The agency has
estimated this burden at 80 hours per
applicant with active applications. The
agency has factored into this estimate
the time it will take industry to identify
and locate the necessary information
within existing records, and to develop
a report that complies with section
512(l)(3) of the act. Once this has been
accomplished, FDA believes that the
process for producing reports in
subsequent years will essentially be
automated, and that it will take
E:\FR\FM\26OCN1.SGM
26OCN1
55048
Federal Register / Vol. 74, No. 205 / Monday, October 26, 2009 / Notices
approximately 3 hours to run a report
that satisfies the act’s requirements. For
sponsors of approved applications that
are inactive (i.e., the approved drug is
not being marketed), the sponsor would
only have to submit a report stating that
the drug is not being marketed, which
FDA estimates will take approximately
1 hour.
FDA has developed a form to report
the information required by section
512(l)(3) of the act. FDA plans to make
the form available to animal drug
manufacturers through FDA’s website
however, use of the form would be
entirely voluntary. The form contains
various fields for information, including
the drug manufacturer’s name, new
animal drug approval number, active
ingredient name, National Drug Code
number, container size, potency, and
the number of units sold by month.
The animal drug manufacturers can
meet the statutory requirements by
submitting their information in paper
format using the FDA-provided form,
one of their own designs, or by
designing their own electronic form
whose results could be submitted to the
agency on a compact disc or on paper.
The cost to animal drug sponsors for
gathering the necessary information for
report design and preparation or for
completing FDA’s form in the first year
of reporting is $107,880 (29 active
sponsors times 80 hours times $46.50
per hour = $107,880). This is a one-time
cost for a computer or mathematic
employees to design and prepare a
report that satisfies the statutory
requirements of section 512(l)(3) of the
act.1 For subsequent years, the
preparation of the report should take
approximately 3 hours. Thus, the total
cost in subsequent years would be
$139.50.
Regarding the recordkeeping burden
associated with this collection of
information, FDA believes that most of
the necessary information for the annual
report required to be submitted under
section 512(l)(3) of the act is already
collected and maintained by animal
drug manufacturers under existing
requirements.
Animal drug manufacturers are
already required to maintain
distribution records for their drug
products to comply with FDA’s current
good manufacturing practice regulations
under § 211.196 (21 CFR § 211.96) (OMB
Control No. 0910–0139), and to comply
with regulations for periodic drug
experience reports under
§ 514.80(b)(4)(i) (21 CFR
§ 514.80(b)(4)(i)) (OMB Control No.
0910–0284) of FDA regulations.
Therefore, FDA believes that
manufacturers of animal drugs already
possess the computers, software, and
additional equipment necessary to
collect and maintain the necessary
records, and to make reports.
Section 512(l)(3) of the act differs
from § 514.80(b)(4)(i) in that it requires
that records include separate
information for each month of the
calendar year. Under § 211.196 (OMB
Control No. 0910–0139), manufacturers
currently are required to maintain
distribution records that include the
dosage form and date the drug is
distributed. Additionally, FDA believes
that manufacturers already keep
detailed records of the dates when
antimicrobial drugs are distributed for
marketing and recall purposes from
which monthly reports can be prepared
as part of their usual and customary
practice. However, FDA estimates
additional hourly burden required by
section 512(l)(3) of the Act as shown in
table 2 of this document.
Dated: October 16, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9–25671 Filed 10–23–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: Parent-Child Assistance
Program (P–CAP) in the Fetal Alcohol
Spectrum Disorder (FASD) Center of
Excellence—New
Since 2001, SAMHSA’s Center for
Substance Abuse Prevention has been
operating a Fetal Alcohol Spectrum
Disorder (FASD) Center of Excellence
which addresses FASD mainly by
providing trainings and technical
assistance; and developing and
supporting systems of care that respond
to FASD using effective evidence based
practices and interventions.
Currently the integration of evidencebased practices into service delivery
organizations is being accomplished
through subcontracts. One such
intervention which integrates
prevention strategies into service
delivery organizations is the ParentChild Assistance Program (P–CAP)
targeting pregnant or postpartum
women. The P–CAP program uses the
following 11 data collection tools.
BILLING CODE 4160–01–S
DESCRIPTION OF INSTRUMENTS/ACTIVITY FOR PARENT-CHILD ASSISTANCE PROGRAM (P–CAP)
Instrument/Activity
Description
At Baseline/Enrollment:
CRSQ ............................................
mstockstill on DSKH9S0YB1PROD with NOTICES
ASI—Part A ...................................
ASI—Part B & Twin ......................
The Community Referral Screening Questionnaire (CRSQ) is a screening form administered to individuals referred to P–CAP. The purpose of the form is to determine eligibility for enrollment in P–CAP.
The Addiction Severity Index (ASI) Part A is an intake interview administered at client enrollment. The
ASI Part A includes questions about past 30-day alcohol use, lifetime use, age at first use, month
and year of last use, range of use (T–ACE), and use during pregnancy, thereby providing a thorough
assessment of alcohol consumption.
The Addiction Severity Index (ASI) Part B is an intake interview administered as soon as possible after
the target child birth. The ASI Part B includes questions about the target child at birth and alcohol
use during the pregnancy. If the target birth is of twins then the Twins Addendum form is administered.
1 BLS Occupation Employment and Wages, May
2006, by occupation, for all industries (https://
www.bls.gov). Wage ($46.50) includes mean hourly
VerDate Nov<24>2008
15:19 Oct 23, 2009
Jkt 220001
wage of $33.22 for Standard Occupational
Classification 15–0000, computer and mathematics
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
occupations, all industries; we add 40 percent to
account for benefits.
E:\FR\FM\26OCN1.SGM
26OCN1
Agencies
[Federal Register Volume 74, Number 205 (Monday, October 26, 2009)]
[Notices]
[Pages 55046-55048]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25671]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0512]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Antimicrobial Animal Drug Distribution Reports Under
Section 105 of the Animal Drug User Fee Amendments of 2008
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
including each proposed extension of a collection of information and to
allow 60 days for public comment in response to the notice. This notice
solicits comments on reporting and recordkeeping requirements for
antimicrobial animal drug distribution as required by Section 105 of
the Animal Drug User Fee Amendments of 2008 (ADUFA).
DATES: Submit written or electronic comments on the collection of
information by December 28, 2009.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or
[[Page 55047]]
provide information to a third party. Section 3506(c)(2)(A) of the PRA
(44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day
notice in the Federal Register concerning each proposed collection of
information before submitting the collection to OMB for approval. To
comply with this requirement, FDA is publishing notice of the proposed
collection of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Antimicrobial Animal Drug Distribution Reports Under Section 105 of the
Animal Drug User Fee Amendments of 2008--Federal Food, Drug, and
Cosmetic Act, Section 512(1)(3) (OMB Control Number 0910-NEW)
Section 105 of ADUFA amended section 512 of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C. 360b) to require that the sponsor
of each new animal drug that contains an antimicrobial agent submit an
annual report to FDA on the amount of each antimicrobial active
ingredient in the drug that is sold or distributed for use in food-
producing animals, including information on any distributor-labeled
product. The legislation was enacted to address the problem of
antimicrobial resistance and to help ensure that FDA has the necessary
information to examine safety concerns related to the use of
antibiotics in food-producing animals (154 Congressional Record H7534).
Each report must specify: (1) The amount of each antimicrobial
active ingredient by container size, strength, and dosage form, (2)
quantities distributed domestically and quantities exported and (3) a
listing of the target animals, indications, and production classes that
are specified on the approved label of the product.
The first report must be submitted not later than March 31, 2010.
The report must cover the period of the preceding calendar year and
include separate information for each month of the calendar year. The
reports required under section 105 of ADUFA are required to be separate
from periodic drug experience reports that are required under 21 CFR
514.80(b)(4) (OMB Control No. 0910-0284).
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
FD&C Act Section 512(1)(3) Respondents per Response Responses Response Total Hours Capital Cost
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual Reports for Sponsors with Active 29 6.7 194 80 15,520 $107,880
Applications
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual Reports for Sponsors with Inactive 23 4.0 92 1 92 ..............
Applications
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total 15,612 $107,880
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no operating and maintenance costs associated with this collection of information.
Table 2.--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
FD&C Act
Section No. of Annual Frequency of Total Annual Hours per Record Total Hours
512(1)(3) Respondents Recordkeeping Records
----------------------------------------------------------------------------------------------------------------
All Applicants 34 1 34 2 68
----------------------------------------------------------------------------------------------------------------
Total 68
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The reporting burden estimates, including the total number of
annual responses, are based on the number of sponsors and approved
applications for antimicrobial drug products in food-producing animals.
The annual frequency of responses was calculated as the total annual
responses divided by the number of respondents.
The agency arrived at the estimates for reporting as follows: There
are 34 sponsors with approved applications for antimicrobial drugs for
food-producing animals. There are 29 animal drug manufacturers with 194
approved applications for antimicrobial drugs for food-producing
animals for which the drugs are being actively marketed (active
applications). Additionally, there are 93 approved applications for
antimicrobial drugs for food-producing animals for which the drugs are
not being marketed (inactive applications), owned by 23 animal drug
manufacturers.
Regarding the reporting burden associated with the collection of
information, FDA believes that the large majority of the burden will be
incurred by industry in the first year in which reporting is required
to design a report that meets the requirements of section 512(l)(3) of
the act. The agency has estimated this burden at 80 hours per applicant
with active applications. The agency has factored into this estimate
the time it will take industry to identify and locate the necessary
information within existing records, and to develop a report that
complies with section 512(l)(3) of the act. Once this has been
accomplished, FDA believes that the process for producing reports in
subsequent years will essentially be automated, and that it will take
[[Page 55048]]
approximately 3 hours to run a report that satisfies the act's
requirements. For sponsors of approved applications that are inactive
(i.e., the approved drug is not being marketed), the sponsor would only
have to submit a report stating that the drug is not being marketed,
which FDA estimates will take approximately 1 hour.
FDA has developed a form to report the information required by
section 512(l)(3) of the act. FDA plans to make the form available to
animal drug manufacturers through FDA's website however, use of the
form would be entirely voluntary. The form contains various fields for
information, including the drug manufacturer's name, new animal drug
approval number, active ingredient name, National Drug Code number,
container size, potency, and the number of units sold by month.
The animal drug manufacturers can meet the statutory requirements
by submitting their information in paper format using the FDA-provided
form, one of their own designs, or by designing their own electronic
form whose results could be submitted to the agency on a compact disc
or on paper. The cost to animal drug sponsors for gathering the
necessary information for report design and preparation or for
completing FDA's form in the first year of reporting is $107,880 (29
active sponsors times 80 hours times $46.50 per hour = $107,880). This
is a one-time cost for a computer or mathematic employees to design and
prepare a report that satisfies the statutory requirements of section
512(l)(3) of the act.\1\ For subsequent years, the preparation of the
report should take approximately 3 hours. Thus, the total cost in
subsequent years would be $139.50.
---------------------------------------------------------------------------
\1\ BLS Occupation Employment and Wages, May 2006, by
occupation, for all industries (https://www.bls.gov). Wage ($46.50)
includes mean hourly wage of $33.22 for Standard Occupational
Classification 15-0000, computer and mathematics occupations, all
industries; we add 40 percent to account for benefits.
---------------------------------------------------------------------------
Regarding the recordkeeping burden associated with this collection
of information, FDA believes that most of the necessary information for
the annual report required to be submitted under section 512(l)(3) of
the act is already collected and maintained by animal drug
manufacturers under existing requirements.
Animal drug manufacturers are already required to maintain
distribution records for their drug products to comply with FDA's
current good manufacturing practice regulations under Sec. 211.196 (21
CFR Sec. 211.96) (OMB Control No. 0910-0139), and to comply with
regulations for periodic drug experience reports under Sec.
514.80(b)(4)(i) (21 CFR Sec. 514.80(b)(4)(i)) (OMB Control No. 0910-
0284) of FDA regulations. Therefore, FDA believes that manufacturers of
animal drugs already possess the computers, software, and additional
equipment necessary to collect and maintain the necessary records, and
to make reports.
Section 512(l)(3) of the act differs from Sec. 514.80(b)(4)(i) in
that it requires that records include separate information for each
month of the calendar year. Under Sec. 211.196 (OMB Control No. 0910-
0139), manufacturers currently are required to maintain distribution
records that include the dosage form and date the drug is distributed.
Additionally, FDA believes that manufacturers already keep detailed
records of the dates when antimicrobial drugs are distributed for
marketing and recall purposes from which monthly reports can be
prepared as part of their usual and customary practice. However, FDA
estimates additional hourly burden required by section 512(l)(3) of the
Act as shown in table 2 of this document.
Dated: October 16, 2009.
David Horowitz,
Assistant Commissioner for Policy.
[FR Doc. E9-25671 Filed 10-23-09; 8:45 am]
BILLING CODE 4160-01-S